In Silico Screening of Available Drugs Targeting Non-Small Cell Lung Cancer Targets: A Drug Repurposing Approach

The RAS–RAF–MEK–ERK pathway plays a key role in malevolent cell progression in many tumors. The high structural complexity in the upstream kinases limits the treatment progress. Thus, MEK inhibition is a promising strategy since it is easy to inhibit and is a gatekeeper for the many malignant effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Thirunavukkarasu, Muthu Kumar, Suriya, Utid, Rungrotmongkol, Thanyada, Karuppasamy, Ramanathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778223/
https://www.ncbi.nlm.nih.gov/pubmed/35056955
http://dx.doi.org/10.3390/pharmaceutics14010059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778223/
https://www.ncbi.nlm.nih.gov/pubmed/35056955
http://dx.doi.org/10.3390/pharmaceutics14010059

Ejemplares similares